The FDA officially announced semaglutide on shortage in March 2022, followed by tirzepatide and dulaglutide in December 2022, and liraglutide in July 2023.(8) Even today, two years later, the supply of these medications remains sparse
Lancet Diabetes Endocrinol 2019;7:356-67.ArticlePubMed 122
Researchers have explored BPC-157 in experimental settings to better understand: Cellular signalling pathways Tissue repair mechanisms Inflammatory response modulation Gastrointestinal tissue integrity in models It is important to emphasise that much of the available data originates from non-human studies , and outcomes observed in laboratory or animal models cannot be assumed to translate to humans
This systemic reach has led researchers to explore whether lower, sustained doses of GLP-1 RAs could maintain receptor activity sufficient to preserve metabolic and organ health without the adverse events often seen with aggressive dosing
The authors proposed that NPY might be protective in the airway, and that loss of NPY might contribute to mucus hypersecretion
Many drugs, especially those that affect the immune system or hormone levels, can cause skin reactions
